Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookfield Renewable Partners

Realty Income Corp

T. Rowe Price Group

Dividend growth stocks tend to outperform, especially in flat to slightly higher markets. AbbVie, Brookfield Renewable, Realty Income, and T.

4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024

Colgate-Palmolive

Chevron

Emerson Electric

JPMorgan Chase & Co

Kimberly-Clark

Walmart

Source: ferrantraite / E+ via Getty Images While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.

7 Dividend Stocks Perfect For Retirement

ImmunoGen

AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

Novo Nordisk

As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innovations, drug discoveries, pending approvals, and market advancements, an element likely to affect their stock price positively.

Pharmaceutical stocks to watch in 2024

GlaxoSmithKline

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product launches, and strategic investments make it an attractive investment option.

AbbVie Vs. GSK: Dual Dominance In Pharma

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Cardinal Health

Caterpillar

Chubb

Church & Dwight

C.H. Robinson Worldwide

Cincinnati Financial

Clorox

Cintas Corp

Dover

Ecolab

The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats by quality score and provide undervalued stocks for further research and investment.

29 Undervalued Dividend Aristocrats: December 2023

AbbVie is a top drugmaker that is putting its free cash flow to use lately with a couple of acquisitions. Abbott Labs has a broader, more diverse business that recently generated double-digit growth.

Better Growth Stock: AbbVie vs. Abbott Laboratories

Broadcom

Mastercard

McDonald's

Altria

UnitedHealth Group

It's always a good time for investors to consider investing in blue-chip dividend stocks. In a sense, this class of equities is amongst the most established and stable investments possible.

7 Blue-Chip Dividend Stocks to Buy Before Dec. 31

Kroger

Microsoft

Public Service Enterprise Group

Visa

Waste Management

Although a new year tends to bring optimism in the market, current vagaries warrant a discussion about bulletproof stocks to buy for 2024. To be fair, even the most influential voices in government are hinting at a positive outcome.

7 ‘Bulletproof' Stocks to Buy Ahead of a Wild New Year

Black Hills

Leggett & Platt

Northwest Natural Gas

Universal Corp

Dividend stocks have always been and will be, among the most compelling choices for investors seeking stable and enduring returns.

Dividend kings: Which stocks continued to increase payouts in 2023?

Molson Coors Brewing

Just for the fun of it and since we did not include it in our Outlook 2024, I decided to have a look at what experts are saying concerning mushrooms, cannabis, and hemp. After all, recreational and medical alternatives as investments, have been huge underperformers and a bit of a legend in their own minds.

Stock(ing) Stuffers That Could Be Lovin the High 2024

Amgen

Con Ed

Hershey

Coca-Cola

Philip Morris

Colgate-Palmolive, Amgen, and others have solid records of increasing dividend payments.

7 Dividend Stocks to Buy as Bond Yields Fall

AT&T

Dividend stocks can be powerful components of a well-diversified income portfolio. AT&T and AbbVie are two popular blue chip dividend stocks known for their high yields.

Better Income Stock: AT&T or AbbVie?

Johnson & Johnson

Pfizer

In the realm of investment, pharma dividend stocks are a beacon for both stability and growth. This sector not only enhances the quality of life on a global scale but also presents lucrative opportunities for long-term investors.

3 of the Most Attractive Dividend Stocks in the Pharma Space

CRISPR Therapeutics

AbbVie's rally has already begun and could continue into the new year. CRISPR Therapeutics received a holiday gift recently with U.S. approval of its first product.

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Apple

General Mills

Hormel Foods

With the markets at or near all time highs, after a wild up and down 2023, I could find comfort in one thing, my dividends. As we all know, the market may move up and down irrationally and seemingly on a whim, while our dividends remain much more stable, reliable and predictable. Another four figures coming in a particular month is nothing to sneeze at. I'll definitely take it, as passive income always seems a little sweeter than active income.

Dividend Income Update November 2023

News for AbbVie Stock (ABBV)